Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 77
Filter
Add more filters

Publication year range
1.
J Phys Ther Sci ; 36(10): 609-613, 2024 Oct.
Article in English | MEDLINE | ID: mdl-39354919

ABSTRACT

[Purpose] This study was aimed at investigating the relationship between skeletal muscle mass and muscle quality by using bioelectrical impedance analysis and ambulatory independence in patients with proximal femoral fractures. [Participants and Methods] The study included 120 patients admitted to a recovery rehabilitation unit for whom follow-up assessments were available. Skeletal muscle mass and phase angle were assessed using bioelectrical impedance analysis upon admission. The patients were divided into the following two groups based on their Functional Independence Measure gait score at discharge: gait-independent group (gait score: ≥6; n=74) and gait-dependent group (gait score: ≤5; n=46). [Results] The phase angle was associated with gait independence. The cut-off values for the phase angle predicting gait independence were 4Ā° and 3.8Ā° for male and female patients, respectively, a more accurate assessment compared with skeletal muscle mass analysis. [Conclusion] The phase angle was associated with gait independence in patients with proximal femoral fractures. The results of this study suggest that the evaluation of the phase angle is important for predicting gait independence in patients with proximal femoral fractures.

2.
J Am Chem Soc ; 145(3): 1505-1511, 2023 Jan 25.
Article in English | MEDLINE | ID: mdl-36547020

ABSTRACT

Multiple-resonance thermally activated delayed fluorescence (MR-TADF) emitters have emerged as an important component of organic light-emitting diodes (OLEDs) because of their narrowband emission and high exciton utilization efficiency. However, the chemical space of MR-TADF emitters remains mostly unexplored because of the lack of suitable synthetic protocols. Herein, we demonstrate a sequential multiple borylation reaction that provides new synthetically accessible chemical space. ω-DABNA, the proof-of-concept material, exhibited narrowband green TADF with a full width at half-maximum of 22 nm and a small singlet-triplet energy gap of 13 meV. The OLED employing it as an emitter exhibited electroluminescence at 512 nm, with Commission International de l'Ɖclairage coordinates of (0.13, 0.73) and a high external quantum efficiency (EQE) of 31.1%. Moreover, the device showed minimum efficiency roll-off, with an EQE of 29.4% at 1000 cd m-2.

3.
Cancer Sci ; 114(8): 3342-3351, 2023 Aug.
Article in English | MEDLINE | ID: mdl-37139543

ABSTRACT

Most multigene mutation tests require tissue specimens. However, cytological specimens are easily obtained in the clinical practice and provide high-quality DNA and RNA. We aimed to establish a test that utilizes cytological specimens and performed a multi-institutional study to investigate the performance of MINtS, a test based on next-generation sequencing. A standard procedure for specimen isolation was defined. The specimens were considered suitable for the test if >100 ng DNA and >50 ng RNA could be extracted from them. In total, 500 specimens from 19 institutions were investigated. MINtS detected druggable mutations in 63% (136 of 222) of adenocarcinomas. Discordant results between MINtS and the companion diagnostics were observed in 14 of 310 specimens for the EGFR gene, and 6 of 339 specimens for the ALK fusion genes. Confirmation by other companion diagnostics for the EGFR mutations or the clinical response to an ALK inhibitor all supported the results obtained by MINtS. MINtS along with the isolation procedure presented in the current study will be a platform to establish multigene mutation tests that utilize cytological specimens. UMIN000040415.


Subject(s)
Lung Neoplasms , Humans , Cytology , Lung Neoplasms/pathology , Mutation , Receptor Protein-Tyrosine Kinases/genetics , RNA
4.
Int J Colorectal Dis ; 37(1): 161-170, 2022 Jan.
Article in English | MEDLINE | ID: mdl-34599685

ABSTRACT

PURPOSE: Colorectal endoscopic submucosal dissection (ESD) produces exfoliated tumor cells that occasionally cause local recurrence. However, the biological characteristics of these tumor cells have not been clarified. The aim of this study was to clarify the genetic background and viability of exfoliated tumor cells in colorectal ESDs, as well as possible method for their elimination. METHODS: Post-ESD intraluminal lavage samples from 19 patients who underwent colorectal ESDs were collected. In four patients with adenocarcinoma, gene mutations in the primary tumors and exfoliated cells in lavage samples were analyzed using a next-generation sequencer (NGS). In 15 patients with adenoma or adenocarcinoma, the viability of exfoliated cells and the cell-killing effect of povidone-iodine on exfoliated cells were evaluated. RESULTS: The analysis using a NGS demonstrated that tumors targeted for ESD had already acquired mutations in many genes involved in cell proliferation, angiogenesis, and invasions. Furthermore, gene mutations between the exfoliated tumor cells and tumors resected by ESDs showed a 92 to 100% concordance. The median viable cell counts and the median viability of exfoliated cells in intraluminal lavage samples after ESDs were 4.9 Ɨ 105 cells/mL and 24%, respectively. The viability of the exfoliated cells did not decrease even 12Ā h after ESD. However, contact with 2.0% povidone-iodine solution reduced both viable cell counts and viability, significantly. CONCLUSION: A large number of tumor cells exfoliated during colorectal ESDs had acquired survival-favorable gene mutations and could survive for some time. Therefore, a lavage using a solution of 2.0% povidone-iodine may be effective against such cells. TRIAL REGISTRATION: The prospective study registered 1317, and the retrospective study registered 2729. The prospective study approved on June 20, 2016, and the retrospective study approved on October 6, 2020.


Subject(s)
Colorectal Neoplasms , Endoscopic Mucosal Resection , Cell Count , Colonoscopy , Colorectal Neoplasms/genetics , Colorectal Neoplasms/surgery , Humans , Prospective Studies , Retrospective Studies , Therapeutic Irrigation , Treatment Outcome
5.
Surg Today ; 52(1): 106-113, 2022 Jan.
Article in English | MEDLINE | ID: mdl-34455492

ABSTRACT

PURPOSE: To evaluate the effect of mild renal dysfunction on the clinical course after colectomy in patients with colon cancer. METHODS: The subjects of this retrospective study were 263 patients who underwent surgical resection for colon cancer at our hospital between 2011 and 2015. Renal function was assessed based on preoperative estimated glomerular filtration rate (eGFR) values. Patients were divided into groups based on their eGFR value of 55Ā ml/min/1.73 m2. The Mann-Whitney U test, chi-square or Fisher exact test, and log-rank test were used in the data analysis. RESULTS: There were 59 patients (22.4%) in the low eGFR group and 204 patients in the normal eGFR group. There were differences between the groups in age, comorbidities, and the levels of hemoglobin, albumin, and serum creatinine. The overall postoperative complication rate, frequency of severe complications, and length of stay were significantly higher in the low eGFR group than in the normal eGFR group. Multivariate analysis revealed that low eGFR was the only independent risk factor for severe complications (Clavien-Dindo classification III/IV). There were no differences in survival between the groups. CONCLUSION: Preoperative asymptomatic renal dysfunction may be correlated with the development of postoperative complications and a possible significant risk factor for severe complications after colon cancer surgery.


Subject(s)
Asymptomatic Diseases , Colectomy , Colonic Neoplasms/surgery , Kidney Diseases/complications , Postoperative Complications/epidemiology , Postoperative Complications/etiology , Aged , Aged, 80 and over , Female , Glomerular Filtration Rate , Humans , Kidney Diseases/diagnosis , Kidney Diseases/physiopathology , Male , Middle Aged , Patient Acuity , Preoperative Period , Prognosis , Retrospective Studies , Risk Factors
6.
Int J Cancer ; 148(3): 769-779, 2021 02 01.
Article in English | MEDLINE | ID: mdl-32895958

ABSTRACT

In patients with pancreatic ductal adenocarcinoma (PDAC), optimal treatment selection, including multimodality regimens such as neoadjuvant chemoradiotherapy (NACRT), can be clinically transformative. Unfortunately, currently no predictive biomarkers are available that can guide the use of NACRT in PDAC patients. Accordingly, herein we developed a novel gene signature that can preoperatively predict NACRT-sensitivity in PDAC patients. Herein, we evaluated the performance of a 10-gene panel in 749 PDAC cases, which included two public datasets (The Cancer Genome Atlas and International Cancer Genome Consortium; n = 276), and three clinical specimen cohorts (n = 417), and a pre-NACRT endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) biopsy cohort (n = 56). The potential predictive performance of this signature was evaluated and compared to CA-19-9 levels and key clinicopathological factors. We first evaluated the prognostic potential of a 10-gene panel which significantly predicted overall survival in both public datasets (P < .01, P < .01), and two in-house patient cohorts (P < .01, P = .04). In the pre-NACRT EUS-FNA cohort, we established a radio-sensitivity gene panel (RSGP) which yielded highly robust (area under the curve [AUC] = 0.91; 95% CI: 0.81-0.97) for predicting response to gemcitabine-based NACRT. Multivariate logistic regression analysis revealed that RSGP was an independent predictor for response to NACRT (OR = 2.70; 95% CI: 1.25-5.85), and this response-prediction was even more robust when CA-19-9 levels were included into the model. In conclusion, we have validated and developed a novel gene signature that is highly robust in predicting response to NACRT, even in preoperative settings, highlighting its clinical significance for optimizing and personalizing treatment strategies in PDAC patients.


Subject(s)
Carcinoma, Pancreatic Ductal/therapy , Gene Expression Profiling/methods , Gene Regulatory Networks , Neoadjuvant Therapy/methods , Pancreatic Neoplasms/therapy , Adult , Aged , Aged, 80 and over , Antigens, Tumor-Associated, Carbohydrate/genetics , Carcinoma, Pancreatic Ductal/diagnosis , Carcinoma, Pancreatic Ductal/genetics , Databases, Genetic , Endoscopic Ultrasound-Guided Fine Needle Aspiration , Female , Gene Expression Regulation, Neoplastic/drug effects , Gene Expression Regulation, Neoplastic/radiation effects , Gene Regulatory Networks/drug effects , Gene Regulatory Networks/radiation effects , Humans , Male , Middle Aged , Pancreatic Neoplasms/diagnosis , Pancreatic Neoplasms/genetics , Survival Analysis , Treatment Outcome
7.
Pancreatology ; 21(3): 573-580, 2021 Apr.
Article in English | MEDLINE | ID: mdl-33541781

ABSTRACT

BACKGROUND: Aberrant expression of CD70 in several malignancies is potentially associated with poor patient prognosis and could serve as a therapeutic target. However, the clinical relevance of CD70 expression in pancreatic cancer has not been thoroughly explored. METHODS: We evaluated CD70 expression in 166 surgical specimens obtained from human patients with pancreatic cancer. We analyzed the function of CD70 in proliferation and migration using pancreatic cancer cell lines with silenced CD70 expression. RESULTS: CD70 expression was positively stained in 42 patients (25%). In the whole cohort, high CD70 expression was not associated with overall survival (OS: 33.1 vs. 40.8 months, PĀ =Ā 0.256), although it was significantly associated with inferior OS in a population of patients that completed adjuvant chemotherapy (OS: 45.4 vs. 63.8 months, PĀ =Ā 0.027). Moreover, the incidence of hematogenous metastasis was significantly higher in patients with high CD70 expression than in those with low CD70 expression (PĀ =Ā 0.020). This finding was also statistically significant in multivariate analyses (PĀ =Ā 0.001). InĀ vitro experiments demonstrated that CD70 expression contributed to cancer cell proliferation independently of gemcitabine treatment as well as cell migration. Furthermore, real-time polymerase chain reaction analysis of frozen surgical tissues showed a correlation between the expression of CD70 and mesenchymal markers. CONCLUSIONS: CD70 expression in pancreatic cancer might be involved in hematogenous metastasis. Furthermore, our results imply that CD70 overexpression can serve as a novel prognostic factor and a potential therapeutic target in patients who have completed adjuvant chemotherapy.


Subject(s)
Biomarkers, Tumor/metabolism , CD27 Ligand/metabolism , Carcinoma, Pancreatic Ductal/metabolism , Carcinoma, Pancreatic Ductal/surgery , Pancreatectomy , Pancreatic Neoplasms/metabolism , Pancreatic Neoplasms/surgery , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/therapeutic use , Carcinoma, Pancreatic Ductal/drug therapy , Carcinoma, Pancreatic Ductal/mortality , Cell Line, Tumor , Cell Movement , Cell Proliferation , Chemotherapy, Adjuvant , Deoxycytidine/analogs & derivatives , Deoxycytidine/therapeutic use , Female , Humans , Male , Middle Aged , Pancreatic Neoplasms/drug therapy , Pancreatic Neoplasms/mortality , Prognosis , Real-Time Polymerase Chain Reaction , Retrospective Studies , Survival Analysis , Gemcitabine
8.
Pancreatology ; 20(5): 867-874, 2020 Jul.
Article in English | MEDLINE | ID: mdl-32654989

ABSTRACT

BACKGROUND: Pancreatectomy may cause serious pancreatic exocrine insufficiency (PEI), which can lead to some nutritional problems, including new-onset diabetes mellitus (DM) or non-alcoholic fatty liver disease (NAFLD). Recent studies have reported that remnant pancreatic volume (RPV) significantly influences postoperative PEI. However, the specific correlation between RPV and postoperative PEI remains unclear. Here, we compare various pre-, peri-, and postoperative risk factors in a retrospective cohort to address whether preoperatively measured RPV is a predictor of postoperative PEI in pancreatic cancer patients after distal pancreatectomy (DP). METHODS: Sixty-one pancreatic cancer patients who underwent DP were retrospectively enrolled. Pancreatic volume was measured using preoperative 3D images, which simulated the actual intraoperative pancreatic parenchymal volume. We obtained the 3D-measured RPV and resected pancreatic volume. We calculated the ratio of the RPV to the total pancreatic volume and then divided the cohort into high- and low-RPV ratio groups based on a cut-off value (>0.35, nĀ =Ā 37 andĀ ≤Ā 0.35, nĀ =Ā 24). Using multivariate analysis, the RPV ratio as well as pre-, peri- and postoperative PEI risk factors were independently assessed. RESULTS: The multivariate analysis revealed that a low RPV ratio (odds ratio [OR], 5.911; pĀ =Ā 0.001), a hard pancreatic texture (OR, 3.313; pĀ =Ā 0.023) and TNM stage III/IV (OR, 3.515; pĀ =Ā 0.031) were strong predictors of the incidence of PEI. CONCLUSIONS: The present study indicates that the RPV ratio is an additional useful predictor of postoperative nutrition status in pancreatic cancer patients.


Subject(s)
Exocrine Pancreatic Insufficiency/diagnostic imaging , Exocrine Pancreatic Insufficiency/etiology , Pancreas/diagnostic imaging , Pancreatectomy/adverse effects , Pancreatic Neoplasms/complications , Pancreatic Neoplasms/diagnostic imaging , Postoperative Complications/diagnostic imaging , Adult , Aged , Aged, 80 and over , Cohort Studies , Female , Humans , Image Processing, Computer-Assisted , Imaging, Three-Dimensional , Male , Middle Aged , Multidetector Computed Tomography , Non-alcoholic Fatty Liver Disease/diagnostic imaging , Pancreatic Function Tests , Pancreatic Neoplasms/surgery , Risk Factors
9.
Langenbecks Arch Surg ; 405(4): 445-450, 2020 Jun.
Article in English | MEDLINE | ID: mdl-32458142

ABSTRACT

PURPOSE: Laugier's hernia is a rare clinical entity compared with a typical femoral hernia. Therefore, the clinical features, radiological findings, and appropriate treatment strategies remain largely unclear. In this study, we present 15 Laugier's hernia cases. Additionally, we review the relevant literature and discuss the clinical features, radiological findings, and appropriate treatment strategies pertaining to Laugier's hernia compared with a typical femoral hernia. METHODS: Among 1260 hernia patients, we retrospectively enrolled 15 Laugier's hernia patients (1.19%) and 89 femoral hernia patients (7.06%) who underwent herniorrhaphy and compared the demographic characteristics and radiological findings between the two groups. RESULTS: Regarding the patient characteristics, a significant difference was observed in the presence of pain (p < 0.001) and ileus symptoms (p = 0.001). Regarding the hernia characteristics, significant differences were observed in the size of the hernial sac (p = 0.001), contents of the hernial sac (p = 0.003), repositioning of the hernial sac (p < 0.001), and repair with polypropylene mesh (p < 0.001). The characteristic multi-detector computed tomography (MDCT) findings enabled the preoperative diagnosis of Laugier's hernia versus conventional femoral hernia. CONCLUSION: Surgeons should be alert to the possibility of atypical femoral hernias while examining femoral hernia or inguinal hernia patients. If Laugier's hernia is suspected, preoperative MDCT is recommended.


Subject(s)
Hernia, Femoral/diagnostic imaging , Hernia, Femoral/surgery , Herniorrhaphy , Aged , Aged, 80 and over , Female , Humans , Male , Multidetector Computed Tomography , Polypropylenes , Retrospective Studies , Surgical Mesh
10.
J Clin Biochem Nutr ; 67(2): 199-205, 2020 Sep.
Article in English | MEDLINE | ID: mdl-33041518

ABSTRACT

Some patients with interstitial pneumonia (IP) have auto-antibodies, but do not fit the criteria for specific connective tissue diseases. Examination of auto-antibodies is recommended for diagnosis idiopathic pulmonary fibrosis. A prospective cohort study was performed in 285 patients with IP. Eleven auto-antibodies were assessed and patients were followed for 2 years. All 285 patients underwent the myositis panel test (MPT) for 11 auto-antibodies. Among them, 23.5% (67/285) of the patients had a positive MPT and 14.7% (42/285) had connective tissue diseases. Among the 49 MPT positive patients without connective tissue diseases, 29 patients (59.2%) were positive for Ro52, including 17 patients with Ro52 mono-positivity. Among interstitial pneumonia patients without connective tissue diseases, the Ro52 mono-positive patients showed worse at 2-years survival than those who were Ro52 negative (pĀ =Ā 0.022, HRĀ =Ā 5.88, 95% CI 1.29-26.75). Most of the Ro52 positive patients also showed a low titer of anti-nucleolar antibody. About 20% of IP patients had auto-antibodies detectable by the MPT, and Ro52 positive patients accounted for more than half of the MPT positive patients without connective tissue diseases. Detection of Ro52 auto-antibodies may be useful for assessing the risk of progression in idiopathic interstitial pneumonia patients without connective tissue diseases and a low anti-nucleolar antibody titer.

11.
Oncologist ; 24(6): 749-e224, 2019 06.
Article in English | MEDLINE | ID: mdl-30679316

ABSTRACT

LESSONS LEARNED: The triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma was an effective treatment that appeared to be better tolerated than the widely used FOLFIRINOX regimen.SOXIRI regimen may provide an alternative approach for advanced pancreatic cancer. BACKGROUND: In our previous phase I study, we determined the recommended dose of a biweekly S-1, oxaliplatin, and irinotecan (SOXIRI) regimen in patients with unresectable pancreatic ductal adenocarcinoma (PDAC). This phase II study was conducted to assess the safety and clinical efficacy in patients with unresectable PDAC. METHODS: Patients with previously untreated metastatic and locally advanced PDAC were enrolled. The primary endpoint was response rate (RR). Secondary endpoints were adverse events (AEs), progression-free survival (PFS), and overall survival (OS). Patients received 80 mg/m2 of S-1 twice a day for 2 weeks in alternate-day administration, 150 mg/m2 of irinotecan on day 1, and 85 mg/m2 of oxaliplatin on day 1 of a 2-week cycle. RESULTS: Thirty-five enrolled patients received a median of six (range: 2-15) treatment cycles. The RR was 22.8% (95% confidence interval [CI]: 10.4-40.1); median OS, 17.7 months (95% CI: 9.8-22.0); and median PFS, 7.4 months (95% CI: 4.2-8.4). Furthermore, the median OS in patients with distant metastasis was 10.1 months, whereas that in patients with locally advanced PDAC was 22.6 months. Major grade 3 or 4 toxicity included neutropenia (54%), anemia (17%), febrile neutropenia (11%), anorexia (9%), diarrhea (9%), and nausea (9%). There were no treatment-related deaths. CONCLUSION: SOXIRI is considered a promising and well-tolerated regimen in patients with unresectable PDAC.


Subject(s)
Adenocarcinoma/drug therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Pancreatic Ductal/drug therapy , Pancreatic Neoplasms/drug therapy , Adenocarcinoma/pathology , Adult , Aged , Carcinoma, Pancreatic Ductal/pathology , Cohort Studies , Drug Combinations , Female , Follow-Up Studies , Humans , Irinotecan/administration & dosage , Male , Middle Aged , Oxaliplatin/administration & dosage , Oxonic Acid/administration & dosage , Pancreatic Neoplasms/pathology , Prognosis , Tegafur/administration & dosage
12.
Pancreatology ; 19(5): 722-728, 2019 Jul.
Article in English | MEDLINE | ID: mdl-31153778

ABSTRACT

BACKGROUND: Although the prognosis of recurrent pancreatic cancer (RPC) is improving with the appearance of new anticancer drugs, prognostic indicators for RPC are still poorly understood. The aim of this study was to evaluate significance of the inflammation-based prognostic score, including modified Glasgow Prognostic Score (mGPS), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), and Prognostic Nutritional Index (PNI), in patients with RPC. METHODS: This study reviewed 263 patients of pancreatic ductal adenocarcinoma at our institution between 2006 and 2015. A receiver operating characteristics curve analysis was performed to determine the cut-off values. The prognostic significance of the inflammation-based prognostic scores were evaluated by a multivariate analysis. RESULTS: 172 patients (65.4%) who had recurrence was included in this study. The optimal PNI for predicting 1-year survival after recurrence was 40 with higher area under receiver operating characteristics curve value (0.704) in comparison with other inflammation-based prognostic scores. A univariate and multivariate analysis revealed that liver metastasis (PĆ¢Ā€ĀÆ<Ć¢Ā€ĀÆ0.001) and PNIĆ¢Ā€ĀÆ<Ć¢Ā€ĀÆ40 (PĆ¢Ā€ĀÆ<Ć¢Ā€ĀÆ0.001) were independently associated with the survival time after recurrence. When each of the two predictors was counted as one point and the points were calculated for all cases, a good stratified survival curve was obtained, showing the shorter survival in the higher points: median survival times of 2, 1, and 0 points were 4.3, 11.1, and 21.2 months, respectively (PĆ¢Ā€ĀÆ<Ć¢Ā€ĀÆ0.001). CONCLUSIONS: Inflammation-based prognostic scores, especially PNI is useful clinical biomarker for predicting the survival time after recurrence in patients with pancreatic adenocarcinoma.


Subject(s)
Carcinoma, Pancreatic Ductal/pathology , Inflammation/pathology , Pancreatic Neoplasms/pathology , Aged , Aged, 80 and over , Carcinoma, Pancreatic Ductal/diagnosis , Carcinoma, Pancreatic Ductal/surgery , Female , Humans , Inflammation/diagnosis , Kaplan-Meier Estimate , Liver Neoplasms/secondary , Lymphocyte Count , Male , Middle Aged , Monocytes , Neoplasm Recurrence, Local , Neutrophils , Nutrition Assessment , Pancreatic Neoplasms/diagnosis , Pancreatic Neoplasms/surgery , Platelet Count , Predictive Value of Tests , Prognosis , Survival Analysis
13.
World J Surg ; 43(2): 626-633, 2019 Feb.
Article in English | MEDLINE | ID: mdl-30225561

ABSTRACT

BACKGROUND: Late-onset gastrointestinal hemorrhage after pancreatoduodenectomy (PD) occasionally occurs repeatedly or leads to a serious condition. This retrospective study aimed to clarify its frequency and pathogenesis. METHODS: A total of 147 consecutive patients who underwent PD for pancreatic cancer between 2006 and 2014 were evaluated. Patients were divided into two groups according to the occurrence of late-onset gastrointestinal hemorrhage on postoperative day 100 or later. Furthermore, recurrence and portal vein (PV) hemodynamics were thoroughly reevaluated by computed tomography. RESULTS: Eleven patients experienced late-onset gastrointestinal hemorrhage. The bleeding sites were gastrojejunostomy in four patients, choledochojejunostomy in two, transverse colic marginal vein in one, and unknown in four. The median occurrence time of late-onset gastrointestinal hemorrhage was 13.3Ā months after PD. PV occlusion (63.6 vs. 8.9%; p < 0.001), no patency of PV-splenic vein (SPV) confluence (54.5 vs. 12.7%; p = 0.002), and SPV ligation (36.4 vs. 9.6%; p = 0.025) were found to be significant risk factors for late-onset gastrointestinal hemorrhage. Among 11 patients who experienced late-onset gastrointestinal hemorrhage, 7 had PV occlusion and 6 had local recurrence. CONCLUSIONS: Our data suggested for the first time that both oncologic and non-oncologic factors might contribute to late-onset gastrointestinal hemorrhage after PD for pancreatic cancer. Furthermore, PV occlusion, no PV-SPV patency, and SPV ligation were found to be significant risk factors for late-onset gastrointestinal hemorrhage. Therefore, to prevent late-onset gastrointestinal hemorrhage, we must consider various approaches to maintain the patency of the PV and SPV.


Subject(s)
Gastrointestinal Hemorrhage/epidemiology , Gastrointestinal Hemorrhage/etiology , Neoplasm Recurrence, Local/pathology , Pancreatic Neoplasms/surgery , Pancreaticoduodenectomy/adverse effects , Portal Vein/physiopathology , Aged , Aged, 80 and over , Female , Hemodynamics , Humans , Ligation , Male , Middle Aged , Portal Vein/pathology , Portal Vein/surgery , Retrospective Studies , Risk Factors , Splenic Vein/surgery , Time Factors , Tomography, X-Ray Computed
14.
World J Surg ; 43(2): 642-648, 2019 Feb.
Article in English | MEDLINE | ID: mdl-30298284

ABSTRACT

BACKGROUND: The optimal stent type in patients receiving preoperative neoadjuvant chemoradiotherapy (NACRT) is uncertain. The present study aimed to compare the clinical effectiveness of biliary metallic stent (MS) and plastic stent (PS) in patients undergoing preoperative NACRT for resectable pancreatic cancer. METHODS: This retrospective study included 43 patients who required either biliary MS or PS before initiating NACRT for resectable or borderline resectable pancreatic head cancer. Seventeen patients had MS (MS group), while 23 patients had PS (PS group). All patients received preoperative NACRT, including gemcitabine and concomitant three-dimensional radiation of 54Ā Gy, and underwent pancreatectomy. Stent patency, surgery postponement, postoperative outcomes, and cost-effectiveness were compared between these groups. RESULTS: There were no significant differences in baseline demographic or tumor characteristics between the groups. Stent patency was significantly longer in the MS group than in the PS group (p = 0.042). There were no differences in time to surgery, intraoperative characteristics, surgical complications, margin positivity, and pathological response between the groups. Furthermore, the medical cost of maintenance of biliary drainage during NACRT was similar between the groups. CONCLUSIONS: MS placement compared to PS in patients receiving preoperative NACRT provided no significant benefits during the postoperative course of pancreatectomy. However, MS placement was associated with long stent patency while showing no economic disadvantage. Therefore, MS placement may be recommended in patients receiving preoperative NACRT for resectable pancreatic cancer.


Subject(s)
Metals , Pancreatic Neoplasms/therapy , Plastics , Stents , Adult , Aged , Antineoplastic Agents/therapeutic use , Chemoradiotherapy, Adjuvant , Deoxycytidine/analogs & derivatives , Deoxycytidine/therapeutic use , Drainage/economics , Female , Health Care Costs , Humans , Male , Middle Aged , Neoadjuvant Therapy , Pancreatectomy , Retrospective Studies , Stents/adverse effects , Treatment Outcome , Gemcitabine
15.
Int J Mol Sci ; 21(1)2019 Dec 30.
Article in English | MEDLINE | ID: mdl-31905926

ABSTRACT

The role of metastasis-related genes in cisplatin (CDDP) chemoresistance in gastric cancer is poorly understood. Here, we examined the expression of four metastasis-related genes (namely, c-met, HMGB1, RegIV, PCDHB9) in 39 cases of gastric cancer treated with neoadjuvant therapy with CDDP or CDDP+5-fluorouracil and evaluated its association with CDDP responsiveness. Comparison of CDDP-sensitive cases with CDDP-resistant cases, the expression of c-met, HMGB1, and PCDHB9 was correlated with CDDP resistance. Among them, the expression of HMGB1 showed the most significant correlation with CDDP resistance in multivariate analysis. Treatment of TMK-1 and MKN74 human gastric cancer cell lines with ethyl pyruvate (EP) or tanshinone IIA (TAN), which are reported to inhibit HMGB1 signaling, showed a 4-5-fold increase in inhibition by CDDP. Treatment with EP or TAN also suppressed the expression of TLR4 and MyD88 in the HMGB1 signal transduction pathway and suppressed the activity of NFκB in both cell lines. These results suggest that the expression of these cancer metastasis-related genes is also related to anticancer drug resistance and that suppression of HMGB1 may be particularly useful for CDDP sensitization.


Subject(s)
Cisplatin/pharmacology , Drug Resistance, Neoplasm/drug effects , Drug Resistance, Neoplasm/genetics , Genes, Neoplasm/drug effects , Stomach Neoplasms/drug therapy , Stomach Neoplasms/genetics , Aged , Aged, 80 and over , Apoptosis , Cell Line, Tumor , Female , Fluorouracil/pharmacology , HMGB1 Protein/genetics , Humans , Male , Middle Aged , Myeloid Differentiation Factor 88/metabolism , NF-kappa B/metabolism , Pancreatitis-Associated Proteins/genetics , Proto-Oncogene Proteins c-met/genetics , Signal Transduction/drug effects , Stomach/pathology , Stomach Neoplasms/pathology , Toll-Like Receptor 4/metabolism
16.
Langenbecks Arch Surg ; 403(6): 693-700, 2018 Sep.
Article in English | MEDLINE | ID: mdl-30218193

ABSTRACT

PURPOSE: Recent advances in multidisciplinary treatments are improving the postoperative prognosis of pancreatic ductal adenocarcinoma (PDAC). However, the prognosis even after potentially curative resection remains poor. The aim of this study was to identify the clinical and pathological features of actual 5-year survivors under current circumstances. METHODS: A total of 128 patients who underwent pancreatectomy for PDAC at our institution between January 2006 and December 2011 were retrospectively analyzed. RESULTS: The actual 5-year overall survival rate for all patients was 30.9%, with a median survival time of 33.1Ā months. Of 128 patients, 25 (19.5%) survived for 5Ā years after surgery without disease recurrence. A univariate analysis showed that the pretreatment serum CA19-9 value, tumor depth, lymph node metastasis, and UICC stage at resection were significant predictive factors for the actual long-term survival. A multivariate analysis showed that a pretreatment serum CA19-9 value ≥ 110Ā U/mL was a significant unfavorable prognostic indicator. In addition, all subjects in the 5-year survival group completed adjuvant chemotherapy. The recurrence rate in the liver was significantly lower and that in the lung significantly higher in the long-term survival group than in the short-term survival group. CONCLUSIONS: The factors contributing to the long-term survival of PDAC were the pretreatment CA19-9 value and the completion of adjuvant chemotherapy. To achieve the actual long-term survival and cure after pancreatectomy for pancreatic cancer, further treatment strategies enhancing the completion rate of adjuvant chemotherapy are required.


Subject(s)
Carcinoma, Pancreatic Ductal/therapy , Pancreatic Neoplasms/therapy , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor/blood , CA-19-9 Antigen/blood , Carcinoma, Pancreatic Ductal/blood , Carcinoma, Pancreatic Ductal/mortality , Carcinoma, Pancreatic Ductal/pathology , Combined Modality Therapy , Female , Humans , Lymphatic Metastasis , Male , Middle Aged , Neoplasm Staging , Pancreatectomy , Pancreatic Neoplasms/blood , Pancreatic Neoplasms/mortality , Pancreatic Neoplasms/pathology , Prognosis , Retrospective Studies , Survival Analysis , Survival Rate
17.
Surg Today ; 48(6): 625-631, 2018 Jun.
Article in English | MEDLINE | ID: mdl-29380135

ABSTRACT

PURPOSES: The relationship between the results of bacterial drainage fluid cultures in the early postoperative period after liver resection and the development of surgical site infections (SSIs) is unclear. We evaluated the diagnostic value of bacterial cultures of drainage fluid obtained on postoperative day (POD) 1 after liver resection. METHODS: The cases of all consecutive patients who underwent elective liver resection from January 2014 to December 2016 were analyzed. The association between a positive culture result and the development of SSIs was analyzed. RESULTS: A total of 195 consecutive patients were studied. Positive drainage fluid cultures were obtained in 6 patients (3.1%). A multivariate analysis revealed that a positive drainage fluid culture was an independent risk factor for SSIs (odds ratio: 8.04, P = 0.035), and combined resection of the gastrointestinal tract was a risk factor for a positive drainage fluid culture (P = 0.006). Among the patients who did not undergo procedures involving the gastrointestinal tract, there was no association between drainage fluid culture positivity and SSIs. CONCLUSIONS: The detection of positive culture results for drainage fluid collected on POD 1 after liver resection was associated with SSIs. However, among patients who did not undergo procedures involving the gastrointestinal tract, it was not a predictor of SSIs.


Subject(s)
Bacteria/metabolism , Bacteriological Techniques/methods , Body Fluids/microbiology , Drainage , Hepatectomy , Surgical Wound Infection/diagnosis , Surgical Wound Infection/microbiology , Adult , Aged , Aged, 80 and over , Bacteria/isolation & purification , Digestive System Surgical Procedures , Elective Surgical Procedures , Female , Gastrointestinal Tract/surgery , Humans , Male , Middle Aged , Postoperative Period , Predictive Value of Tests , Risk Factors , Time Factors
18.
Proc Natl Acad Sci U S A ; 110(16): 6536-41, 2013 Apr 16.
Article in English | MEDLINE | ID: mdl-23550157

ABSTRACT

The cytoplasmic RNA-induced silencing complex (RISC) contains dsRNA binding proteins, including protein kinase RNA activator (PACT), transactivation response RNA binding protein (TRBP), and Dicer, that process pre-microRNAs into mature microRNAs (miRNAs) that target specific mRNA species for regulation. There is increasing evidence for important functional interactions between the miRNA and nuclear receptor (NR) signaling networks, with recent data showing that estrogen, acting through the estrogen receptor, can modulate initial aspects of nuclear miRNA processing. Here, we show that the cytoplasmic RISC proteins PACT, TRBP, and Dicer are steroid receptor RNA activator (SRA) binding NR coregulators that target steroid-responsive promoters and regulate NR activity and downstream gene expression. Furthermore, each of the RISC proteins, together with Argonaute 2, associates with SRA and specific pre-microRNAs in both the nucleus and cytoplasm, providing evidence for links between NR-mediated transcription and some of the factors involved in miRNA processing.


Subject(s)
Carrier Proteins/metabolism , DEAD-box RNA Helicases/metabolism , Gene Expression Regulation/genetics , MicroRNAs/metabolism , RNA-Binding Proteins/metabolism , RNA-Induced Silencing Complex/metabolism , Ribonuclease III/metabolism , Blotting, Western , Cell Fractionation , Chromatin Immunoprecipitation , Cloning, Molecular , HEK293 Cells , HeLa Cells , Humans , Luciferases , MCF-7 Cells , Plasmids/genetics , RNA Interference , Reverse Transcriptase Polymerase Chain Reaction , Transfection , Two-Hybrid System Techniques
19.
Gan To Kagaku Ryoho ; 43(12): 1875-1877, 2016 Nov.
Article in Japanese | MEDLINE | ID: mdl-28133161

ABSTRACT

A 69-year-old man underwent esophagogastroduodenoscopy, which showed a slightly depressed lesion at the greater curvature of the gastric body. We diagnosed gastric adenocarcinoma of the fundic gland type(GA-FG)from examination of the biopsy specimen. Endoscopic submucosal dissection(ESD)was performed for curative resection. The pathological examination revealed a positive vertical margin. Consequently, laparoscopic gastrectomy was additionally performed. GA-FG has recently been proposed as a new entity of gastric adenocarcinoma. GA-FG mostly develops without Helicobacter pylori infection and often invades the submucosa, regardless of size. However, GA-FG rarely demonstrates lymphatic and venous invasion despite deep submucosal invasion. Since most GA-FG cases undergo ESD, few reports of surgical resection exist. Here, we report our experience of laparoscopic gastrectomy for GA-FG.


Subject(s)
Adenocarcinoma/surgery , Stomach Neoplasms/surgery , Aged , Biopsy , Gastrectomy , Humans , Laparoscopy , Male , Stomach Neoplasms/pathology , Treatment Outcome
20.
Pancreatology ; 15(3): 240-6, 2015.
Article in English | MEDLINE | ID: mdl-25888010

ABSTRACT

BACKGROUND: There is increasing need to evaluate the surgical indication of pancreatic cancer in very elderly patients. However, the available clinical data are limited, and the optimal treatment is still controversial. The aim of this study was to evaluate the benefit of pancreatic resection in pancreatic cancer patients over the age of 80. METHODS: Between 2005 and 2012, 26 octogenarian patients who received pancreatic resection and 20 who received chemotherapy for pancreatic cancer were retrospectively reviewed. Clinicopathological factors, chemotherapy administration status, and survival were compared. Univariate and multivariate analysis of prognostic factors for survival was performed. RESULTS: Postoperative major complication rate was 8%, with no mortality. The one-year survival rate and median survival time of the surgery and chemotherapy groups were 50% and 45%, and 12.4 months and 11.7 months, respectively (P = 0.263). Of the 26 resected cases, 6 completed the planned adjuvant chemotherapy treatment course. The median survival time of those 6 completed cases was significantly longer than that of the 20 not completed cases (23.4 versus 10.0 months, P = 0.034). Furthermore, a multivariate analysis of the 26 resected cases showed that distant metastasis (HR 3.206, 95%CI 1.005-10.22, P = 0.049) and completion of the planned adjuvant therapy (HR 4.078, 95%CI 1.162-14.30, P = 0.028) were independent prognostic factors of surgical resection. CONCLUSIONS: Surgical resection was safe, but not superior to chemotherapy for pancreatic cancer in octogenarians. In the very elderly, only selected patients may benefit from pancreatic resection.


Subject(s)
Adenocarcinoma/surgery , Pancreatectomy , Pancreatic Neoplasms/surgery , Adenocarcinoma/drug therapy , Adenocarcinoma/mortality , Age Factors , Aged, 80 and over , Antineoplastic Agents/therapeutic use , Chemotherapy, Adjuvant , Deoxycytidine/analogs & derivatives , Deoxycytidine/therapeutic use , Drug Combinations , Female , Humans , Male , Multivariate Analysis , Oxonic Acid/therapeutic use , Pancreatic Neoplasms/drug therapy , Pancreatic Neoplasms/mortality , Postoperative Complications/epidemiology , Prognosis , Retrospective Studies , Survival Analysis , Tegafur/therapeutic use , Treatment Outcome , Gemcitabine
SELECTION OF CITATIONS
SEARCH DETAIL